1-(5-Chloro-1H-indol-2-yl)heptan-1-one | 934615-38-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-(5-Chloro-1H-indol-2-yl)heptan-1-one
• CAS: 934615-38-0
• 化学式: C₁₅H₁₈ClNO
• 分子量: 263.767
• InChiKey: QXPLOEWATQSSMY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  32.9
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(5-Chloro-1H-indol-2-yl)heptan-1-one 在 aluminum (III) chloride 、 双(三甲基硅烷基)氨基钾 、 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 、 苯 为溶剂， 生成
  参考文献：
  名称：

  Discovery of N-Aryl-2-acylindole human glucagon receptor antagonists

  摘要：

  A novel class of N-aryl-2-acylindole human glucagon receptor (hGCGR) antagonists is reported. These compounds demonstrate good pharmacokinetic profiles in multiple preclinical species. One compound from this series, indole 33, is orally active in a transgenic murine pharmacodynamic model. Furthermore, a 1 mg/kg oral dose of indole 33 lowers ambient glucose levels in an ob/ob/hGCGR transgenic murine diabetes model. This compound was deemed suitable for preclinical safety studies and was found to be well tolerated in an 8-day experimental rodent tolerability study. The combination of preclinical efficacy and safety observed with compound 33 highlights the potential of this class as a treatment for type 2 diabetes. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.09.105
• 作为产物：
  描述：

  5-氯吲哚-2-羧酸 在 1-羟基苯并三唑 、 1,2-二氯乙烷 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 生成 1-(5-Chloro-1H-indol-2-yl)heptan-1-one
  参考文献：
  名称：

  Discovery of N-Aryl-2-acylindole human glucagon receptor antagonists

  摘要：

  A novel class of N-aryl-2-acylindole human glucagon receptor (hGCGR) antagonists is reported. These compounds demonstrate good pharmacokinetic profiles in multiple preclinical species. One compound from this series, indole 33, is orally active in a transgenic murine pharmacodynamic model. Furthermore, a 1 mg/kg oral dose of indole 33 lowers ambient glucose levels in an ob/ob/hGCGR transgenic murine diabetes model. This compound was deemed suitable for preclinical safety studies and was found to be well tolerated in an 8-day experimental rodent tolerability study. The combination of preclinical efficacy and safety observed with compound 33 highlights the potential of this class as a treatment for type 2 diabetes. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.09.105

文献信息

• Acyl indoles, compositions containing such compounds and methods of use
  申请人：Kim M. Ronald

  公开号：US20070088071A1

  公开（公告）日：2007-04-19

  The present invention relates to substituted indoles, compositions containing such compounds and methods of treatment The compounds are glucagon receptor antagonists and thus are useful for treating, preventing or delaying the onset of type 2 diabetes mellitus and related conditions.

  本发明涉及替代吲哚类化合物，含有这种化合物的组合物，以及治疗方法。这些化合物是胰高血糖素受体拮抗剂，因此可用于治疗、预防或延缓2型糖尿病及相关疾病的发生。
• HETEROCYCLIC COMPOUND
  申请人：Banno Yoshihiro

  公开号：US20120053173A1

  公开（公告）日：2012-03-01

  Provision of a prophylactic or therapeutic agent for diabetes, which has superior efficacy. A compound represented by the formula: wherein each symbol is as described in the specification, or a salt thereof.

  为糖尿病提供一种具有卓越疗效的预防或治疗药物。该化合物由以下公式表示：其中每个符号如规范所述，或其盐。
• Heterocyclic compound
  申请人：Banno Yoshihiro

  公开号：US08436043B2

  公开（公告）日：2013-05-07

  Provision of a prophylactic or therapeutic agent for diabetes, which has superior efficacy. A compound represented by the formula: wherein each symbol is as described in the specification, or a salt thereof.

  提供一种预防或治疗糖尿病的药物，其疗效优异。该化合物的表示式为：其中每个符号如说明书所述，或其盐。
• US7598398B2
  申请人：——

  公开号：US7598398B2

  公开（公告）日：2009-10-06
• US8436043B2
  申请人：——

  公开号：US8436043B2

  公开（公告）日：2013-05-07